用β阻塞剂治疗心力衰竭:我们能做得更好吗?
Mucio Tavares de Oliveira1,2, Rui Baptista3,4,5,6, Sergio A Chavez-Leal7
1Heart Institute, Day Hospital and Infusion Center, University of Sao Paulo Medical School, Sao Paulo, Brazil.
Current medical research and opinion
|April 10, 2024
概括
β抑制剂对于治疗心力衰竭 (HF),改善症状,生存和减少住院治疗至关重要. 优化β-阻断剂剂量对于改善HF患者的治疗结果至关重要.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭 (HF) 涉及交感神经系统过度激活,导致不良的心脏重塑和不良预后.
- 目前的HF管理强调症状控制和并发症,而不是仅排气分数 (LVEF).
研究的目的:
- 审查β阻塞剂在治疗心力衰竭与减少喷射率 (HFrEF) 和心力衰竭与保存喷射率 (HFpEF) 中的作用和疗效.
- 突出beta阻断剂定位对于最佳患者治疗结果的重要性.
主要方法:
- 对现有的随机化,安慰剂对照试验和专家意见的审查,对HF的β-阻断剂治疗.
- 对β-阻断剂对症状,生存,住院和特定患者群体的影响的分析.
主要成果:
- β阻塞剂改善HF症状,功能状态,存活率,并减少心力衰竭在HFrEF的住院治疗.
- 在HFpEF中,β抑制剂提供抗缺血和心率降低的效果,并降低糖尿病,CKD和COPD等并发症患者的死亡率.
- 更高的β-阻断剂剂与改善的临床结果相关.
结论:
- β抑制剂是HFrEF的基础疗法,对HFpEF有益,特别是在并发症中.
- 适当的β阻塞剂剂量定位对于最大限度地使患者在心力衰竭管理中的益处至关重要.
- 可能考虑组合治疗,包括β-阻断剂,RAAS抑制剂/neprilysin抑制剂,MRA和SGLT2抑制剂.
相关概念视频
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
01:22Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
01:26Heart Failure Drugs: Inotropic Agents
577
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
577
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
794
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
794
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
442
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
442